As of today (2024-12-13), the Trailing Annual Dividend Yield of NextCure is 0.00%.
The historical rank and industry rank for NextCure's Dividend Yield % or its related term are showing as below:
NXTC's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.42 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
NextCure Dividend Yield % Historical Data
The historical data trend for NextCure's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NextCure's Dividend Yield %
For the Biotechnology subindustry, NextCure's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure's Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where NextCure's Dividend Yield % falls into.
NextCure Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
NextCure (NAS:NXTC) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of NextCure's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NXTC has been successfully added to your 